24535-11-3

Basic information

• Product Name: 3-hydroxypropanehydrazide
• Synonyms: 3-hydroxypropanehydrazide
• CAS NO: 24535-11-3
• Molecular Formula: C₃H₈N₂O₂
• Molecular Weight: 104.10782
• EINECS: -0
• Mol File: 24535-11-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 103-104 °C
• Boiling Point: 382.1°Cat760mmHg
• Flash Point: 184.9°C
• Appearance: /
• Density: 1.222g/cm³
• Vapor Pressure: 2.07E-07mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 13.07±0.18(Predicted)
• CAS DataBase Reference: 3-hydroxypropanehydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxypropanehydrazide(24535-11-3)
• EPA Substance Registry System: 3-hydroxypropanehydrazide(24535-11-3)

Safety Data

• Hazardous Substances Data: 24535-11-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C3H8N2O2/c4-5-3(7)1-2-6/h6H,1-2,4H2,(H,5,7)

Upstream product

• 57-57-8 β-Propiolactone 
• 623-72-3 ethyl 3-hydroxypropanoate 
• 6149-41-3 methyl ester (3-hydroxy) propionic acid 

Relevant articles and documents

Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface

Rational designs of small-molecule inhibitors targeting protein-protein interfaces have met little success. Herein, we have designed a series of triazole derivatives with a novel scaffold to specifically intervene with the interaction of TLR8 homomerization. In multiple assays, TH1027 was identified as a highly potent and specific inhibitor of TLR8. A successful solution of the X-ray crystal structure of TLR8 in complex with TH1027 provided an in-depth mechanistic insight into its binding mode, validating that TH1027 was located between two TLR8 monomers and recognized as an unconventional pocket, thereby preventing TLR8 from activation. Further biological evaluations showed that TH1027 dose-dependently suppressed the TLR8-mediated inflammatory responses in both human monocyte cell lines, peripheral blood mononuclear cells, and rheumatoid arthritis patient specimens, suggesting a strong therapeutic potential against autoimmune diseases.

OXADIAZOLE LINKERS AND USE THEREOF

Provided is oxadiazole linkers and use thereof, more specifically to the compounds represented by formulas (I), (II), and (III), and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula (I), (II), and (III) is the same as that in the description.

HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.